![[U.S. Food and Drug Administration]](https://webarchive.library.unt.edu/eot2008/20081104081705im_/http://www.fda.gov/icon/header.gif)
Clinical Therapeutics and the Recognition of Drug-Induced Disease
Learning Objectives:
Upon completion of this program, health professionals should be able to:
- Understand the importance of postmarketing drug surveillance
- Identify basic limitations of premarketing clinical trials in the detection of adverse drug reactions
- Explain how the pharmacokinetic and pharmacodynamic properties of a drug influence its efficacy and expected toxicity
- List the types of adverse drug reactions
- Describe the thought process involved in recognizing an adverse drug event (ADE)
- Differentiate which ADEs to report to the Food and Drug Administration's (FDA) MedWatch program
Return to the Table of Contents
![[FDA Home Page]](https://webarchive.library.unt.edu/eot2008/20081104081705im_/http://www.fda.gov/icon/iconhome.gif)